Clinic
Sunrise Treatment Center, LLC
Sunrise Treatment Center, LLC was paid $130.12M by Medicaid between Jan 2018 and Dec 2024, across 68 billing codes. Its largest line is T1502, Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit — 31% of everything it billed.
33Billing provider infoSUNRISE TREATMENT CENTER, LLC
CINCINNATI, OH 45247
CINCINNATI, OH 45247
33aNPI1992043053assigned 01/24/2013
33bProvider typeAdult Mental Health Clinic/Center
28Total paid$130.12M
24GClaims1,739,885
24DCodes billed68
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Adult Mental Health Clinic/Center providers in Ohio
Rank by total paid#1 of 42
Median peer was paid$652K
This provider vs. median200×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 197,083 | $10.40M | |
| 2019 | 231,843 | $14.96M | |
| 2020 | 282,528 | $18.58M | |
| 2021 | 208,778 | $17.87M | |
| 2022 | 244,280 | $19.94M | |
| 2023 | 326,238 | $24.84M | |
| 2024incomplete | 249,135 | $23.52M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | 31% | 254,666 | 105,920 | $40.24M |
| S5000 | Prescription drug, generic | 31% | 300,394 | 94,958 | $40.02M |
| S5001 | Prescription drug, brand name | 4.6% | 26,432 | 9,596 | $6.03M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 4.2% | 94,157 | 52,349 | $5.50M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.7% | 41,208 | 37,452 | $4.83M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.2% | 92,654 | 59,873 | $4.12M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education | 3.1% | 24,180 | 5,720 | $4.03M |
| 90837 | Psychotherapy session, about an hourPsychotherapy, 53 minutes with patient | 3.0% | 38,543 | 24,774 | $3.89M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 2.8% | 30,857 | 24,068 | $3.69M |
| H0048 | Alcohol and/or other drug testing: collection and handling only, specimens other than blood | 2.7% | 250,483 | 141,288 | $3.57M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 2.5% | 203,501 | 81,645 | $3.21M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.8% | 32,844 | 23,315 | $2.30M |
56 more codes
| 90834 | Psychotherapy session, about 45 minutes | 1.4% | 26,193 | $1.80M |
| 90832 | Psychotherapy session, about 30 minutes | 1.4% | 33,947 | $1.80M |
| J3490 | Unclassified drugs | <1% | 6,888 | $756K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | <1% | 53,419 | $596K |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 26,880 | $450K |
| 99205 | Prolong outpt/office vis | <1% | 1,621 | $326K |
| T1003 | Lpn/lvn services, up to 15 minutes | <1% | 12,594 | $277K |
| 80362 | <1% | 16,700 | $269K | |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 4,496 | $234K |
| 80348 | <1% | 23,506 | $210K | |
| 80354 | <1% | 23,420 | $209K | |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | <1% | 18,210 | $180K |
| 80346 | <1% | 11,872 | $166K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,915 | $152K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 882 | $131K |
| J2315 | Injection, naltrexone, depot form, 1 mg | <1% | 94 | $118K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,604 | $91K |
| 80364 | <1% | 5,437 | $89K | |
| T1002 | Rn services, up to 15 minutes | <1% | 2,446 | $83K |
| H0006 | Alcohol and/or drug services; case management | <1% | 1,317 | $49K |
| 80365 | <1% | 5,316 | $48K | |
| 80335 | <1% | 4,847 | $44K | |
| 80338 | <1% | 4,781 | $44K | |
| 80342 | <1% | 4,723 | $43K | |
| 80360 | <1% | 4,785 | $43K | |
| 80357 | <1% | 4,733 | $43K | |
| 80369 | <1% | 4,708 | $43K | |
| 80373 | <1% | 4,695 | $43K | |
| 80368 | <1% | 4,701 | $43K | |
| 80358 | <1% | 4,534 | $41K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 212 | $38K |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 298 | $31K |
| 80349 | <1% | 2,821 | $26K | |
| 82075 | <1% | 1,358 | $25K | |
| 80324 | <1% | 2,687 | $25K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,460 | $25K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 211 | $20K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 1,697 | $19K |
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 827 | $10K |
| H0001 | Alcohol and/or drug assessment | <1% | 215 | $9K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 122 | $7K |
| 81025 | <1% | 1,566 | $7K | |
| 90785 | <1% | 573 | $7K | |
| 80353 | <1% | 685 | $6K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 210 | $5K |
| 86580 | <1% | 1,040 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 175 | $4K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 19 | $2K |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | <1% | 709 | $2K |
| 80359 | <1% | 157 | $1K | |
| G2074 | Medication assisted treatment, weekly bundle not including the drug, including substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) | <1% | 100 | $717.12 |
| G2079 | Take-home supply of buprenorphine (oral); up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 496 | $406.63 |
| 83992 | <1% | 27 | $378.25 | |
| 80367 | <1% | 12 | $113.53 | |
| J0578 | Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy | 0% | 12 | $0.00 |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAIR, NICHOLE (CREDENTIALING MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Sunrise Treatment Center, LLC | Cincinnati, OH | $1.02M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.